Randomized Phase 2 Trial Of Brentuximab Vedotin Or Crizotinib (Commercially Labeled) In Combination With Chemotherapy For Newly Diagnosed Patients With Anaplastic Large Cell Lymphoma (ALCL)

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Anaplastic Large Cell Lymphoma
  • Age: Between 0 - 22 Years
  • Gender: Male or Female
  • Other Inclusion Criteria:

    1. Patient must have newly diagnosed histologically proven Anaplastic Large cell lymphoma, must be CD30 positive, ALK positive, with Stage II, III, or IV disease

    2. Life expectancy greater than 8 weeks

You may not be eligible for this study if the following are true:

  • 1. Patients with central nervous system disease, disease limited to the skin, and Stage I ALCL

    2. Prior cytotoxic chemotherapy for the current diagnosis of ALCL

    3. Previous steroid treatment and/or radiation treatment (unless for emergent management of a mediastinal mass)

    4. Pregnancy or lactation

    5. Patients with an immunodeficiency, Down syndrome, or organ transplant recipients are ineligible

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.